Overview

Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrin Tumor (pNET)

Status:
Active, not recruiting

Trial end date:
2021-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare STZ vs everolimus as first line treatment for advanced pNET and to elucidate which sequence of streptozotocin (STZ) based chemotherapy and the mammalian Target of Rapamycin (mTOR) inhibitor, everolimus, gives better results in terms of second Progression Free Survival (PFS) in well differentiated and advanced pancreatic NETs.

Phase:

Phase 3

Details

Lead Sponsor:

Grupo Espanol de Tumores Neuroendocrinos

Collaborators:

European Neuroendocrine Tumor Society
Kantar Health
Novartis Pharmaceuticals

Treatments:

Everolimus
Fluorouracil
Sirolimus